Date: 2018-04-27
Type of information: Grant
Company: Sangamo Therapeutics (USA - CA)
Investors: California Institute for Regenerative Medicine (CIRM) (USA - CA)
Amount: $8 million
Funding type: grant
Planned used:
- The grant will be used to evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia. Sangamo's Investigational New Drug Application for ST-400 has been accepted by the FDA and the first site is now initiated for a Phase 1/2 clinical trial. Sangamo expects to begin enrolling patients in this study in the first half of 2018.
Others:
- • On April 27, 2018, Sangamo Therapeutics announced that the California Institute for Regenerative Medicine (CIRM) has awarded an $8 million grant for Sangamo to evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia.
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases
Is general: Yes
